Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | THRA | P10827 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11947670 | 0.88 | MTNR1A (0.39) | CNR1CNR2MTNR1AMTNR1BL3MBTL1 | |
| SCHEMBL21864682 | 0.88 | MTNR1A (0.39) | CNR1CNR2MTNR1AMTNR1BL3MBTL1 | |
| SCHEMBL14295932 | 0.88 | MTNR1A (0.39) | CNR1CNR2MTNR1AMTNR1BL3MBTL1 | |
| SCHEMBL85885 | 0.88 | MTNR1A (0.39) | CNR1CNR2MTNR1AMTNR1BL3MBTL1 | |
| SCHEMBL16284392 | 0.88 | MTNR1A (0.39) | CNR1CNR2MTNR1AMTNR1BL3MBTL1 | |
| SCHEMBL10198852 | 0.79 | MTNR1A (0.46) | MTNR1AMTNR1BHTTTHRATHRB | |
| SCHEMBL12444102 | 0.77 | MTNR1A (0.43) | MTNR1AMTNR1BHTTSMN1; SMN2CHEK2 | |
| SCHEMBL19445539 | 0.76 | MTNR1A (0.41) | MTNR1AMTNR1BMAPK14HTTTHRA | |
| SCHEMBL13351617 | 0.75 | HTT (0.40) | MTNR1AMTNR1BMAPK14HTTSMN1; SMN2 | |
| SCHEMBL12515465 | 0.75 | MTNR1A (0.43) | MTNR1AMTNR1BHTTSMN1; SMN2CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120258141-A9 | Methods Of Immune Modulation | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-10-11 | — | — | US | disclosed |
| US-8129566-B2 | Polycationic compounds and uses thereof | POLYMEDIX, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20120039945-A1 | Methods Of Immune Modulation | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-02-16 | — | — | US | disclosed |
| US-20110124664-A1 | Polycationic Compounds And Uses Thereof | POLYMEDIX, INC. (US) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258141-A9 | Methods Of Immune Modulation | IFNG, CD14, TLR3 | CNR1 996/4885CNR2 772/4885MTNR1A 748/4885 |
| US-20120039945-A1 | Methods Of Immune Modulation | IFNG, CD14, TLR3 | CNR1 996/4885CNR2 772/4885MTNR1A 748/4885 |
| US-20110124664-A1 | Polycationic Compounds And Uses Thereof | VEGFA, VHL, PGF | CNR1 2408/4885CNR2 2031/4885MTNR1A 1915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.